Pharmafile

APRIL 23, 2024

Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib 400mg twice daily oral treatment in adult patients with persistent or chronic immune thrombocytopenia (ITP).

Immunity 59

Immunity Immunization 59

European Pharmaceutical Review

DECEMBER 12, 2023

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. Innate Pharma is an international clinical-stage biotechnology oncology company based in France. Can you describe Innate Pharma’s clinical stage pipeline?

Immunity 111

Immunity Immunization Chemotherapy Pharmaceutical Companies 111

World Pharma News

MARCH 19, 2024

A new cancer treatment that uses a person’s own immune cells has been approved by the U.S. Now this form of cellular therapy (tumor-infiltrating lymphocyte - or TIL therapy) is showing promise in advanced lung cancers through clinical trials underway at The Ohio State University Comprehensive Cancer Center - Arthur G.

Immunity 75

Immunity Immunization Hospitals 75

European Pharmaceutical Review

OCTOBER 20, 2022

Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?mediated What are Tregs and how are they applicable to immune-mediated disease?

Immunity 127

Immunity Immunization Drug Development 127

Express Pharma

JULY 7, 2023

Preliminary data from the OCTAVE study in August 2021 showed that a significant proportion of clinically at-risk patients with immunocompromised or immunosuppressed conditions, mounted a low, or undetectable, immune response after two doses of the same SARS-CoV-2 vaccine.

Immunity 94

Immunity Immunization Vaccines Hospitals 94

Pharmaceutical Technology

APRIL 10, 2023

Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. The company strengthens the translational research collaboration between the US and Ireland.

Immunity 103

Immunity Immunization Drug Development 103

STAT

APRIL 29, 2024

Daiichi Sankyo and AstraZeneca said their targeted cancer drug Enhertu showed a  statistically significant and clinically meaningful slowing  of tumor progression in a randomized, Phase 3 study involving patients with hormone-positive, HER2-low metastatic breast cancer.

Immunity 229

Immunity Immunization Vaccines 229

STAT

JANUARY 21, 2024

LONDON — Starting Monday, a new, highly effective malaria vaccine will be rolled out for the first time, as an immunization campaign for children kicks off in Cameroon — a day that global health officials say marked a historic step in the decades-long quest to protect people from one of the world’s deadliest infections.

Vaccines 363

Vaccines Immunity Immunization 363

Pharmaceutical Technology

JUNE 30, 2023

Immune Thrombocytopeniais under clinical development by NovelMed Therapeutics and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).

Immunity 52

Immunity Immunization 52

Pharmaceutical Technology

APRIL 17, 2023

Clinical-stage biotechnology company Smart Immune has secured $5m in equity investment from the Bill & Melinda Gates Foundation for expediting the development of its thymus-empowered ProTcell platform for the treatment of cancer and infectious diseases. SMART 101 is produced from healthy donor-mobilised peripheral blood.

Immunity 52

Immunity Immunization 52

World Pharma News

SEPTEMBER 18, 2023

(Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, VVD-130037.

Immunity 108

Immunity Immunization 108

The Pharmacist

MARCH 29, 2023

Dysregulation of an immune cell appears to underpin specific symptoms in patients with long Covid, researchers have said. Writing in […] The post Patterns of immune cell dysregulation lined to long Covid, study suggests appeared first on The Pharmacist.

Immunity 52

Immunity Immunization 52

pharmaphorum

OCTOBER 26, 2022

has exited stealth with a $65 million Series A to create a new class of medicines that target novel I-O mechanisms, which free the body’s normal immunity against cancer. Called “immune normalisers”, these targets are drawn from an ongoing and interactive academic-biotech research alliance within the Yale School of Medicine.

Immunity 52

Immunity Immunization 52

Outsourcing Pharma

OCTOBER 21, 2020

The US agency has launched a large clinical trial to examine the viability of using immune modulators to treat patients hospitalized with COVID-19.

Immunity 80

Immunity Immunization Hospitals 80

Pharmaceutical Technology

FEBRUARY 8, 2024

NiKogene is under clinical development by Kian Immune Cell and currently in Phase I for Pediatric Diffuse Intrinsic Pontine Glioma.

Immunity 40

Immunity Immunization 40

pharmaphorum

AUGUST 20, 2021

Bristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Exscientia, paying $20 million for the buy-in as part of their $1.2 The post BMS buys into AI-designed immune drug from Exscientia appeared first on. billion alliance.

Immunity 98

Immunity Immunization 98

NY Times

JULY 4, 2021

France is handing out third shots of the two-dose vaccines to cancer patients and others with immune system impairments. In the United States, patients like these are on their own.

Immunity 89

Immunity Immunization Vaccines 89

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. ” The post AstraZeneca’s intranasal COVID vaccine fails first clinical test appeared first on.

Vaccines 113

Vaccines Immunity Immunization 113

Pharmaceutical Technology

JULY 6, 2022

Scientists at the National Institutes of Health (NIH) unit National Institute of Neurological Disorders and Stroke (NINDS) have found that Covid-19-induced immune response could damage the blood vessels of the brain and may lead to short and long-term neurological symptoms. .

Immunity 64

Immunity Immunization 64

pharmaphorum

AUGUST 2, 2022

In May, another amyloid targeting drug for Alzheimer’s disease – AC Immune and Roche’s crenezumab – missed the mark in another clinical trial and looked destined for the scrap heap like so many drugs in the class before it. The post AC Immune tries to resurrect crenezumab with new data delve appeared first on.

Immunity 52

Immunity Immunization 52

pharmaphorum

MARCH 15, 2021

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. One of these involves listening to what the body’s own immune system can tell us. This is made possible using ‘Advanced Host Immune Response Technologies’.

Immunity 70

Immunity Immunization Vaccines 70

Outsourcing Pharma

NOVEMBER 16, 2021

have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D). CRISPR Therapeutics and ViaCyte, Inc.

Diabetes 111

Diabetes Immunity Immunization 111

Pharmaceutical Technology

DECEMBER 20, 2023

LC-002 is under clinical development by Genetic Immunity and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS).

Immunity 40

Immunity Immunization 40

STAT

NOVEMBER 28, 2023

The negative study, called ADVANCE-SC, was the second of two clinical trials involving the Argenx drug called efgartigimod in patients with primary immune thrombocytopenia (ITP), a debilitating condition that destroys blood-clotting platelets. Argenx shares were down 12% in early trading.

Immunity 259

Immunity Immunization Drug Development 259

Digital Pharmacist

JULY 11, 2023

One effective strategy to achieve this is by offering top-notch clinical services that not only enhance patient care but also contribute to a significant revenue boost. Immunizations & Vaccinations Independent pharmacies are ideally positioned to provide convenient immunization services to their communities.

Independent Pharmacies 98

Independent Pharmacies Medication Therapy Management (MTM) Compounding Scheduling Appointments 98

pharmaphorum

DECEMBER 4, 2020

The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. The post 4th Antigen Specific Immune Tolerance Summit appeared first on.

Immunity 52

Immunity Immunization Medical Schools Drug Development 52

STAT

FEBRUARY 16, 2024

Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. This is hopefully the first of many to come.”

Immunity 363

Immunity Immunization 363

European Pharmaceutical Review

NOVEMBER 16, 2023

In the past couple of months, BeiGene has experienced regulatory progress for two of its oncology assets in clinical development. What is the main challenge in advancing a drug through the clinical development process? Clinical trials account for over 90 percent of the cost and time of developing a new medicine.

Immunity 52

Immunity Immunization 52

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. For our vaccine, we use two different adenovirus vectors in a bid to avoid the immune system becoming immune to the vector.”.

Immunity 106

Immunity Immunization Vaccines Hospitals 106

Pharmacy Times

JUNE 3, 2023

Fecal microbiota transplant from responders to non-responders was able to rescue immune checkpoint inhibition use in patients with melanoma, with 40% of patients showing clinical benefit.

Immunity 52

Immunity Immunization 52

BioPharma Dive

MAY 9, 2023

The buyout of privately held XinThera continues a string of recent acquisitions of smaller biotechs by Gilead and hands it a group of drug prospects that could begin clinical testing later this year.

Immunity 106

Immunity Immunization 106

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is administered through intravenous and subcutaneous route.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

Outsourcing Pharma

JANUARY 30, 2023

The company will set up a clinical trial site network alongside sponsors, CROs, and health systems, for colorectal cancer and immune health.

Immunity 52

Immunity Immunization 52

pharmaphorum

DECEMBER 6, 2021

A trial of booster vaccinations to protect against COVID-19 has shown that the jab significantly strengthens the body’s T-cell immunity against the disease. All of these boosted immunity in younger and older people with varying efficacy. The post COVID booster shots increase immunity, trial shows appeared first on.

Immunity 52

Immunity Immunization Vaccines Hospitals 52

STAT

DECEMBER 7, 2022

When tumors like melanoma form, the immune system mobilizes for war. White blood cells called lymphocytes rush to assault the tumor — but cancer has ways of disabling the immune system. But those immune cells still have the potential to kill cancer cells. It’s called TIL, or tumor infiltrating lymphocyte therapy.

Immunity 255

Immunity Immunization 255

European Pharmaceutical Review

FEBRUARY 6, 2023

David Hallett, PhD, Chief Scientific Officer at Exscientia explained: “PKC theta is an attractive immune modulating drug target; however, it has been challenging for the field to design a small molecule with the required potency as well as selectivity against other closely related kinases.”

Compounding 89

Compounding Immunity Immunization 89

PharmaShots

APRIL 5, 2023

maintenance phase results showed a dose-linear increase in clinical remission, 10 & 30mg, qd of vidofludimus calcium showed clinical remission rate (42.3% & 61.5% vs 27.8%); steroid-free clinical remission rate (38.5% & 61.5% vs 27.8%); steroid-free clinical remission rate (38.5% & 61.5%

Immunity 40

Immunity Immunization 40